Diligence memo · auto-generated · as of July 2, 2026

Immunaeon Inc.

Immunaeon Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Immunaeon Inc. operates in Biotechnology, based in BUFFALO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Immunaeon Inc. has raised $250K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $250K on 2023-02-23.

Most recent recorded round closed around 2023-02-23.

Valuation (modeled)modeled

Provath models Immunaeon Inc. at approximately $2.7M (range $133K–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.83× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (83% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 3.4 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 6% of Biotechnology peers (4293 compared).

Modeled value ranks above 6% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.